摘要
目的:系统评价苓桂术甘汤加减治疗非酒精性脂肪性肝病(NAFLD)的效果和安全性。方法:计算机检索PubMed、中国生物医学文献服务系统(SinoMed)、万方、维普、知网等数据库,查找苓桂术甘汤加减治疗NAFLD的临床随机对照试验研究文献,起止时间为建库至2021年5月,提取相关研究数据,选用RevMan 5.4软件对数据进行系统分析。结果:7篇临床随机对照研究文献符合纳入标准,共收集研究病例608例。Meta分析结果显示:苓桂术甘汤加减改善谷丙转氨酶[MD=-11.69,95%CI(-15.31,-8.06),P<0.00001]、谷草转氨酶[MD=-8.48,95%CI(-13.62,-3.35),P=0.001]、甘油三酯[MD=-0.98,95%CI(-1.60,-0.36),P=0.002]、总胆固醇[MD=-0.88,95%CI(-1.19,-0.56),P<0.00001]、胰岛素抵抗指数[MD=-1.39,95%CI(-1.62,-1.15),P<0.00001]水平均优于对照组。结论:苓桂术甘汤加减治疗NAFLD有效,且安全性良好。
Objective:To systematically evaluate the efficacy and safety of Lingguizhugan Decoction in the treatment of non-alcoholic fatty liver disease(NAFLD).Method:Computer searched PubMed,China Biomedical Literature Service System(SinoMed),Wanfang,Weipu,CNKI and other databases,searched for clinical randomized controlled trial research literature of Lingguizhugan Decoction in the treatment of NAFLD,the start and stop time was to build the database-May 2021,extract relevant research data,and use RevMan 5.4 software to perform systematic analysis on the data.Result:Seven clinical randomized controlled research literatures met the inclusion criteria,and a total of 608 research cases were collected.Meta-analysis results showed that the addition and subtraction of Lingguizhugan Decoction improved the levels of alanine aminotransferase[MD=-11.69,95%CI(-15.31,-8.06),P<0.00001],aspartate aminotransferase[MD=-8.48,95%CI(-13.62,-3.35),P=0.001],triglyceride[MD=-0.98,95%CI(-1.60,-0.36),P=0.002],total cholesterol[MD=-0.88,95%CI(-1.19,-0.56),P<0.00001],insulin resistance index[MD=-1.39,95%CI(-1.62,-1.15),P<0.00001]were better than those of the control group.Conclusion:Lingguizhugan Decoction is effective in the treatment of NAFLD and has good safety.
作者
秦和英
杨柳青
孙克伟
QIN Heying;YANG Liuqing;SUN Kewei(Hunan University of Chinese Medicine,Changsha 410007,China;不详)
出处
《中国医学创新》
CAS
2022年第2期176-180,共5页
Medical Innovation of China
基金
湖南中医药大学中医学国内一流学科建设学科项目(湘教通[2018]469号)。
